Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesPharmacologic therapy for inflammatory bowel disease refractory to steroidsGolimumab for the treatment of ulcerative colitis.Methotrexate for Inflammatory Bowel Diseases - New DevelopmentsOptimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Vedolizumab for the treatment of moderately to severely active ulcerative colitis.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Biologic agents for IBD: practical insights.Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.Next-Generation Therapeutics for Inflammatory Bowel Disease.Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know.Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancerA microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow.The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.Benzimidazoles Promote Anti-TNF Mediated Induction of Regulatory Macrophages and Enhance Therapeutic Efficacy in a Murine Model.Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.Acute severe ulcerative colitis: latest evidence and therapeutic implications.Thiopurine Metabolism in the Era of Combotherapy.Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.Combination Therapy for Inflammatory Bowel Disease.
P2860
Q24185835-40B51A98-76E8-4909-A941-F8AE72BD93D6Q26796415-2F9FCE79-E680-4C41-A1BF-17B7A2789F7CQ33852257-A8B05062-D98E-4474-B18E-462EAF7E1587Q34518393-BEFDAA18-E9AC-4C31-9E70-87008AD4F89EQ35561386-65C1B684-DA90-415E-BE4A-CEE81130A3DCQ38425873-55747490-8ED1-4A2A-A1F9-DE86740FBFB9Q38563075-C1DF2FAA-A684-43D1-970C-4373D3AAB1C8Q38568898-5D60F089-3EFE-40EC-8CB8-9BFC43A49D7AQ38669977-4821D734-21DA-4C5D-9F41-CF2C1A117E58Q38719570-5A27876A-A6BD-4706-B18E-A1886F985A7FQ38789642-8F44FC94-C288-45F8-A448-791CB6C2C327Q38909523-CB1D8AE5-610B-4397-AA44-2680F88B6C37Q39140194-2639E0A9-D40D-4CCF-AC5E-CDE858972569Q40070921-A822C83B-238C-465F-8883-B64ADC82538FQ40703329-38C03B3D-A10A-4522-8700-53696690FCFEQ42151036-3673F146-3BD5-4071-9CEC-10CBCCF34F13Q42176588-6B0660F2-F9E2-49F3-AA5C-9FB210D3A41CQ42687364-2FFFCF71-49AF-4A43-9495-F2BD8B25FF70Q46279754-3DD65C09-FD3E-4607-88C4-D2F0140E3E45Q47109861-4906BE85-658A-4C65-A596-0A3BC198F3B7Q47361114-C430F412-97AC-4C9D-B62A-A9E7294814D8Q47898039-373F2E71-32DD-4150-8EDA-BC6851973579Q48224314-E3C5F9C6-8C27-4E34-882E-0C26DC660621Q49232336-F8BED43E-CD8C-43AB-8DA8-5E0638C00376Q50691937-382B1475-82C1-49E2-839F-1F8A600237E9Q51063874-9EA51D07-5333-43B7-AC7E-8CA982BFAF00Q52721523-022C0E03-30A1-4D06-AC72-23C795377080Q54157729-9D91BB51-6D41-4B3F-93AD-47B1D053CAEB
P2860
Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systematic review: Monotherapy ...... an immunosuppressive for IBD.
@en
type
label
Systematic review: Monotherapy ...... an immunosuppressive for IBD.
@en
prefLabel
Systematic review: Monotherapy ...... an immunosuppressive for IBD.
@en
P50
P1433
P1476
Systematic review: Monotherapy ...... an immunosuppressive for IBD.
@en
P2093
Corey A Siegel
Parambir S Dulai
P304
P356
10.1136/GUTJNL-2014-307126
P407
P577
2014-06-26T00:00:00Z